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Abstract: Photodynamic therapy (PDT) is an emerging cancer therapy that uses the 
combination of non-toxic dyes or photosensitizers (PS) and harmless visible light to 
produce reactive oxygen species and destroy tumors. The PS can be localized in various 
organelles such as mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus and 
plasma membranes and this sub-cellular location governs much of the signaling that occurs 
after PDT. There is an acute stress response that leads to changes in calcium and lipid 
metabolism and causes the production of cytokines and stress response mediators. 
Enzymes (particularly protein kinases) are activated and transcription factors are 
expressed. Many of the cellular responses center on mitochondria and frequently lead to 
induction of apoptosis by the mitochondrial pathway involving caspase activation and 
release of cytochrome c. Certain specific proteins (such as Bcl-2) are damaged by  
PDT-induced oxidation thereby increasing apoptosis, and a build-up of oxidized proteins 
leads to an ER-stress response that may be increased by proteasome inhibition. Autophagy 
plays a role in either inhibiting or enhancing cell death after PDT. 
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1. Introduction 
Photodynamic therapy (PDT) is a promising therapeutic procedure for the management of a variety 
of solid tumors and non-malignant lesions. PDT is a two-step procedure that involves the 
administration of a photosensitizing agent [1-3], followed by activation of the drug with non-thermal 
light of a specific wavelength [4,5] (Figure 1). The anticancer effect of PDT is a consequence of a low-
to-moderately selective degree of photosensitizer (PS) uptake by proliferating malignant cells, direct 
cytotoxicity of reactive oxygen species (ROS) and a severe vascular damage that impairs blood supply 
to the treated area [6,7]. Those biological effects of PDT are limited to the particular areas of tissues 
exposed to light. Additionally, PDT leads to activation of tumor directed, systemic immune  
responses [8-10].  
Figure 1. Schematic illustration of the mechanism of Photodynamic therapy (PDT). The 
photosensitizer (PS) is injected systemically and after sufficient time to allow its 
accumulation in the lesion light is delivered to produce reactive oxygen species (ROS). 
The tumor cells are killed by a mixture of necrosis and apoptosis, the blood supply is 
damaged and the host immune system activated. 
 
 
After the absorption of photons the PS is transformed from its ground state to its triplet excited state 
via a short-lived excited singlet state (Figure 2) [11]. The triplet state can undergo two different 
reactions: (i) it can undergo electron or hydrogen atom transfer reactions with oxygen or a substrate 
producing free radicals and other reactive oxygen species; (ii) it can transfer its energy directly to 
ground-state triplet oxygen to form excited state singlet oxygen (Figure 3). The first process is called a 
type I reaction and the second a type II reaction [4]. The PDT effectiveness is therefore determined by 
oxygen supply and may be decreased in conditions where there is tissue hypoxia [12].  
PDT as a treatment procedure has been accepted by the United States Food and Drug 
Administration for use in endo-bronchial and endo-esophageal cancer [13,14] and also as a treatment 
of premalignant and early malignant lesions of skin (actinic keratosis), bladder, breast, stomach and 
oral cavity [4,15]. 
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Figure 2. Jablonski diagram. Ground state PS absorbs a photon of correct wavelength to 
excite its electron to first excited singlet state that may (in addition to losing energy by heat 
or fluorescence emission) undergo intersystem crossing to long lived triplet state. This can 
undergo photochemistry by either electron transfer (Type I) or by energy transfer (Type II) 
to molecular oxygen to produce ROS. 
 
Figure 3. Photodynamic effect. An excited triplet state can either react directly with a 
reductant, e.g., an organic molecule in a cellular microenvironment, acquiring a hydrogen 
atom or electron to form a radical and produce a superoxide anion radical (O2
•-
), type I 
reaction or, more likely, transfer its energy to molecular oxygen (
3
O2) and form singlet 
oxygen (
1
O2), type II reaction. 
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The available body of literature suggests that there is clearly no single pathway that leads to cell 
death after PDT. In the present review we aim to describe and summarize different cell death pathways 
activated by PDT [16,17] and describe the key players controlling cell death related to PDT (Table 1). 
Table 1. Major cell death mechanism activated by Photodynamic therapy (PDT). 
Anti-tumor PDT mechanisms 
Direct cell damage 
Organelles Processes 
Mitochondria: 
 Cytochrome c release 
 Bcl-2 damage Apoptosis 
Cytoplasm: 
 NFκB damage 
Endoplasmatic reticulum: 
 Beclin 1,  
 mTOR activation 
Autophagy 
Cell membrane disintegration Necrosis 
Vascular shutdown Local depletion of oxygen and nutrients 
Apoptosis 
Necrosis 
Autophagy 
Activation of immune response Cytotoxic T cells 
Granzyme 
mediated 
apoptosis 
2. PDT and Apoptosis 
Apoptosis is a very complex, multi-step, multi-pathway cell-death program that is genetically 
encoded in every cell of the body [18]. It can be initiated either through the activation of death 
receptors or the mitochondrial release of cytochrome c [19]. Both events eventually lead to activation 
of caspase cascades known as ‗executioner caspases‘ such as caspase-3, -6 and -7 [20,21]. The active 
executioner caspases cleave cellular substrates, which leads to characteristic biochemical and 
morphological changes observed in dying cells [22]. Cleavage of nuclear lamins is followed by 
chromatin condensation and nuclear shrinkage; cleavage of the inhibitor of the DNase CAD (caspase 
activated deoxyribonuclease) causes DNA fragmentation. Cleavage of cytoskeletal proteins leads to 
cell fragmentation and formation of apoptotic bodies [23]. The apoptotic process is tightly controlled 
by various proteins [24,25]. It is well known that resistance of tumor cells to apoptosis might be an 
essential feature of cancer development thus, modulation of the key elements of apoptosis signaling 
may directly influence therapy-induced tumor-cell death [26,27].  
2.1. Involvement of Bcl-2 Family in PDT Response 
In mammals the Bcl-2 family has at least 20 relatives, all of which share at least one conserved Bcl-2 
homology domain. The family includes four other anti-apoptotic proteins: BclXL, Bcl-w, A1 and Mcll, 
and two groups of proteins that promote apoptosis: the Bax and the BH3-only families [28,29]. 
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2.1.1. The Pro-Survival Family 
Bcl-2 and other members of the family potently inhibit apoptosis in response to many, but not all 
cytotoxic insults. Bcl-2 itself is required for the survival of kidney and melanocyte stem cells and 
mature lymphocytes [30], BclXL for neuronal and erythroid cells [31], and Bcl-w for sperm 
progenitors [32]. Bcl-2 and several other pro-survival molecules associate with the mitochondria outer 
membrane and the endoplasmic reticulum/nuclear membrane and maintain their integrity [33]. They 
can prevent cytochrome c release and subsequent caspase 9 activation. They probably also regulate the 
activation of several other caspases, independently of mitochondrial damage [34]. 
PDT is thought to induce photodamage of Bcl-2 and related antiapoptotic proteins and activate the 
proapoptotic members of the family [35]. Alteration in expression of members of Bcl-2 family proteins 
following PDT has been reported in various cell lines and tumors. Lutetium texaphyrin mediated PDT 
induced apoptosis in bovine retinal capillary endothelial (BRCE) cells involved changes in Bcl-2 and 
Bax levels while in human retinal pigment epithelial (RPE) cells changes in Bcl-xL and Bak proteins 
were observed [36]. The PDT resistant HT29 human colon adenocarcinoma cell line showed variation 
in numerous genes and proteins including upregulation of Bcl-2 levels and downregulation of Bax [37]. 
Apoptotic death induced by 5-aminolevulinic (5-ALA) mediated PDT involved suppression of bcl-2 
mRNA levels and elevation of Bax mRNA in cervical cancer cell line [38] and esophageal cancer cell [39]. 
This regimen also let to increase in Bax/Bcl-2 ratio in human malignant glioblastoma U87MG cells [40] 
while in U937 cells increase in Bak and Bax/Bcl-xL but decrease in Bid was observed [41]. 5ALA-
PDT also caused a significant decrease in mRNA expression of Bcl-2 and increased the levels of Bax 
and Bad mRNA in cervical cancer in BALB/c nude mice [42]. Hypericin (HY) mediated PDT in human 
breast adenocarcinoma cell line involved downregulation of Bcl-xl and upregulation of Bax [43]. 
However, HY-PDT did not affect Bcl-2 levels in p53 null and wt-p53 expressing HCT 116 cells [44]. 
These studies indicated a possible involvement of the antiapoptotic Bcl-2 family members in PDT 
induced apoptotic cell death, but a more definite role for Bcl-2 comes from studies involving antisense 
treatment and overexpression approaches. 
In the study by He et al. [45], employing a pair of Chinese hamster ovary cell lines that differed 
from one another by a transfected Bcl-2 gene, the ability of this gene to modulate PDT- induced 
apoptosis was investigated. PS used was a silicon phthalocyanine compound termed ‗Pc4‘. Data from 
this research indicate that parental cells displayed a high incidence of apoptosis following PDT 
procedure, whereas Bcl-2-transfected cells exhibited a much lower incidence of apoptosis as assessed 
by DNA fragmentation by gel electrophoresis, flow cytometry and fluorescence microscopy. The 
clonogenic assays demonstrated that Bcl-2 was able to inhibit overall cell killing as well.  
Kim et al. [46], however, reported a contradictory finding wherein overexpression of Bcl-2 in a 
subline of human breast epithelial cell MCF10A made them more sensitive to photodamage mediated 
by aluminum phthalocyanine. It was reasoned that transfection of Bcl-2 led to overexpression of both 
Bcl-2 and Bax. The mitochondrial photodamage resulted in selective degradation of Bcl-2 without 
affecting Bax, thereby increasing Bax: Bcl-2 ratio. A higher ratio is known to promote initiation of 
apoptosis [47], thus explaining the contradictory results. Similar results were obtained in a study by 
Srivastava et al. [48]. The two employed cell lines (RIF1 and A431) differed in their response to  
Pc4-PDT-induced apoptosis in antisense treatment and overexpression approaches. It was found that 
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the overexpression of Bcl-2 in PDT apoptosis- sensitive human epidermoid carcinoma (A431) caused 
an enhanced apoptosis as well as increased Bax protein levels. Consequently, there was an increase in 
the Bax/Bcl-2 ratio that was associated with an increased apoptotic response. In the same study, the 
antisense Bcl-2 oligonucleotide was also used. Treatment of RIF1 cells with antisense oligonucleotide 
resulted in the significant reduction of their viability in the concentration-dependent manner as 
compared with cells treated with scrambled nucleotide. PDT treatment of apoptosis resistant RIF1 cells 
with antisense Bcl-2 oligonucleotide resulted in a significant induction of apoptosis 6 h following 
PDT. The antisense treatment was shown to result in enhanced caspase activity following PDT as 
compared to cells treated with PDT alone. The increase in caspase activity was maximal at 3 h post-
PDT and declined at 6 h post-PDT. The team also observed that the antisense treatment resulted in 
significant PARP cleavage at 6 h post-PDT. The effect of antisense Bcl-2 oligonucleotide on the 
protein expression of Bcl-2 was assessed by immunoblot analysis and ELISA. Both assays 
demonstrated an almost 2-fold decrease in the protein expression of Bcl-2 in cells treated with 
antisense followed by PDT and a concentration-dependent decrease in the level of Bcl-2 with a 
concomitant increase in the extent of apoptosis. This decrease correlated with the increased sensitivity 
of RIF1 cells to PDT induced apoptosis. PDT of A431 cells, which were sensitive to PDT-mediated 
apoptosis, resulted in a significant time-dependent down-regulation of Bcl-2 protein. The 
overexpression approach of Bcl-2 resulted in an increase in apoptosis by PDT as compared to the 
normal wild type A431 cells. Moreover, the overexpression of Bcl-2 protein enhanced the  
PDT-mediated caspase activity indicating the increase in apoptosis.  
This study documented that down-regulation of Bcl-2 with antisense oligonucleotide resulted in 
sensitization of PDT apoptosis-resistant cells to apoptosis; however, the overexpression of Bcl-2 in a 
PDT apoptosis-sensitive cell line resulted in the enhancement of the apoptotic response.  
A similar approach was used in human gastric adenocarcinoma MGC803 cell line which was 
infected with antisense bcl-2 RNA retrovirus vector to study effect of 2-butylamino-2-demethoxy-
hypocrellin A (2-BA-2-DMHA) photosensitization [49]. A significant reduction in Bcl-2 protein 
expression accompanied by an increased phototoxicity and susceptibility to apoptosis was observed.  
Granvile et al. [50] in his overexpression model using benzoporphyrin derivative monoacid ring A 
(BPD-MA) and human acute myelogenous leukemia HL-60 cells observed that Bcl-2 overexpression 
may influence caspase 3 and caspase 6 activation and prevent the appearance of hypo-diploid DNA 
induced by PDT. However Bcl-2 overexpression was less effective at preventing cell death that 
occurred after photoactivation at high levels of PS. 
A study performed by Kim et al. [51] showed that Bcl-2 transfection of MCF10A adhering human 
breast epithelial cell line resulted in a decrease in the light dose required for 90% loss of viability. Four 
hours after irradiation a substantial number of apoptotic cells were detected in the transfected subline, 
along with a markedly diminished intensity of MTO fluorescence. The authors concluded that a 
subline of MCF10A transfected with Bcl-2 was more sensitive to the lethal effects of PDT, showed a 
greater apoptotic response and a more rapid and extensive activation of caspase-3-like activity. 
Another work indicating possible role of Bcl-2 in PDT response was reported by Xue et al. [52]. In 
this study it was shown that the anti-apoptotic protein Bcl-2 was highly sensitive to PDT mediated 
damage. It was observed that immediately following Pc4-PDT there was a marked reduction in the 
amount of Bcl-2 detected on the blot. Although there appeared to be a slow partial recovery of the  
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Bcl-2 level in the cells 2 h post PDT, the control level was not restored. Overexposure of the same blot 
revealed the presence of a trace amount of a 23 kDa fragment in the treated cells. The loss of Bcl-2 
was dose dependent and was observed for both endogenous and overexpressed Bcl-2 in several lines. 
The authors concluded that Bcl-2 was a target of PDT with Pc4, and PDT damage of the protein 
contributed to the efficient induction of apoptosis. 
The study indicating that Bcl-2 may by a potential target in PDT, was also performed by  
Kessel et al. [53]. In this project by using 3 different photosensitizers classified as ‗mitochondrial‘ (tin 
etiopurpurin, 9-capronyloxy-tetrakis porphyrin and meta-tetrahydroxyphenyl chloride) selective 
photodamage of Bcl-2 was observed, whereas the other family members were undamaged. This 
situation led to a substantial increase in Bax/Bcl-2 ratio, which has been described as a critical factor in 
PDT induced apoptosis. 
This team provided additional evidence to the hypothesis that Bcl-2 photodamage can be a target for 
some photosensitizing agents by showing that the effects of the photosensitizer CPO can be mimicked 
by the Bcl-2 antagonist HA14-1 [54]. 
2.1.2. The Pro-Apoptotic Family 
The BH3-only proteins seem to act as damage sensors and direct antagonists of the pro-survival 
proteins, whereas the Bax like proteins act further downstream, probably in mitochondrial disruption. 
The BH3-only proteins are sentinels that can detect developmental death cues or intracellular damage. 
In healthy cells, they are restrained in diverse ways, including sequestration by the cytoskeleton. When 
unleashed by death signals, they switch off survival function by inserting their BH3 domain into a 
groove on their pro-survival relatives [55]. During apoptosis, Bax and Bak oligomerize in the 
mitochondria outer membrane and probably break its integrity, freeing pro-apoptotic proteins like 
cytochrome c, which allows the activation of caspase 9 [29]. 
The possible role of Bax in PDT-mediated apoptosis was showed by Srivastava et al. [56], when 
assessing the impact of PDT on the status of Bax protein in Bcl-2-overexpressing A431 cells. Using 
immunoblot analysis it was shown that PDT resulted in an increased level of Bax protein in these cells 
as compared with normal A431 cells and increase in Bax/Bcl-2 ratio. 
The research performed by Usuda et al. [57] further supported the role of Bax in PDT-mediated cell 
death. The results indicated that Pc4-PDT caused the release of the Bax protein from the mitochondria 
of MCF7c3 cells but not from those of Bax-negative DU-145 cells. It was also observed that the 
apoptosis in Bax transfected cells was greater than in non-transfected cells. 
Accumulating evidence suggests that PDT is an efficient inducer of apoptosis in many cancer cell 
lines, whereas the lack of the ability to undergo apoptosis does not protect cells from lethal effects of 
PDT. It therefore appears that the post-mitochondrial regulators, such as Bax protein, may be in the 
promotion of the late events of tumor responses. Thus, tumor cells with increased Bax/Bcl-2 ratio can 
be more effectively treated by PDT.  
Bax was found to translocate to mitochondria during apoptosis in HeLa cells after PDT with zinc 
(II) phthalocyanine [58]. Npe6 mediated PDT involved Bax protein as indicated by a study in Lewis 
lung carcinoma cells transfected with IL-6 that have higher Bax protein levels than the parent cells. 
Bax was also induced remarkably by NPe6 mediated PDT in the transfected cells. Moreover the 
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decreases in the expression of Bcl-2 after PDT in LLC and LLC-IL-6 cells were similar thereby 
eliminating modulation of Bcl-2 expression levels by PDT as an explanation in this case [59]. The 
dependence of Pc4-PDT induced apoptosis on Bax remains under active investigation and reports from 
Chiu et al. [60,61] indicated that commitment to cell death after PDT occurs prior to Bax activation 
while Usuada et al. [62] reported that Smac/DIABLO promotes apoptosis after Pc4-PDT in a Bax 
dependent manner. Furthermore, Bax was not found to be essential for Photofrin-PDT induced 
apoptosis in human lung adenocarcinoma cells (ASTC-a-1) [63]. In the absence of Bax/Bak, 
autophagy appears to be predominantly responsible for cell death following PDT with different 
photosensitizers [64-66].  
3. Cytochrome c Release after PDT 
It is generally recognized that mitochondria play a critical role in the apoptotic cascade by 
controlling the release of crucial factors involved in that process [67]. Among these factors cytochrome 
c plays an essential role. During the process of apoptosis, cytochrome c is released from mitochondria 
into the cytosol. Release of cytochrome c from mitochondria is controlled by proteins of the Bcl-2 
family. In the cytosol, cytochrome c activates the caspases—a family of killer proteases—through 
formation of a complex with Apaf-1 (for apoptotic-protease activating factor-1), procaspase-9 and 
ATP or dATP. [68]. The opening of the mitochondrial membrane permeability transition pores, which 
results in the dissipation of the mitochondrial membrane potential (m), has been proposed as the 
main mechanism for release of cytochrome c. Chiu and Olenick [69], showed that treatment of LY-R 
cells with Pc4 based PDT resulted in release of cytochrome c to the cytoplasm after 15 min, as 
estimated by an immunohistochemical method, and the loss of m depended on PDT dose and the 
post treatment time. The observed loss of m was only in those cells receiving the highest dose of 
PDT. It was concluded that the release of cytochrome c from mitochondria is independent of the loss 
of m action after Pc4 mediated PDT.  
Another work indicating an important role of cytochrome c in PDT-induced apoptosis was carried 
out by Vantieghem et al. [70]. In his approach, the overexpression of Bcl-2 in Pc60R1R2 cells 
revealed that mechanism of cytochrome c release after hypericin mediated PDT is caspase-dependent. 
The observed overexpression of Bcl-2 remarkably delayed cytochrome c release, but it did not 
protected cells from PDT induced death. These results showed that in cells overexpressing Bcl-2 
addition of zVAD-fmk significantly suppressed cytochrome c release and apoptosis.  
Another support for the hypothesis that cytochrome c plays a vital role in PDT-induced apoptosis 
was provided by Varnes et al. [71]. In this study, an LD99.9 dose of Pc4 PDT induced loss of cytochrome c 
from the mitochondria of LY-R cells, but also inhibited respiration and caused activation of caspase 3-
like proteases. All events took place within 15 min of light exposure. This study provided clear 
evidence that cytochrome c leakage is dependent on activation of proteolytic proteases after PDT. 
4. Involvement of Death Receptors in PDT Response 
All death receptors belong to TNFR superfamily (tumor necrosis factor receptor) [72]. Most of them 
act as transmembrane signal transducers that respond to ligand binding. Some of them, however, do 
not transduce signals, but rather function as decoy receptors that compete for the interaction of cognate 
Cancers 2011, 3              
 
 
2524 
ligands with their signaling receptors. Each member of the TNFR superfamily has at least one specific 
ligand, but there are other ligands that bind to several receptors. The most complex example is 
APO2/TRAIL, which binds five different receptors [73].  
TNFR signaling was discovered to be an important factor in immune response and such members 
like Fas and APO2/TRAIL induce apoptosis through a p-53 independent mechanism. The signaling 
members of TNFR superfamily can be divided into two main subgroups. One class contains 
cytoplasmic death domain, whereas the other class does not. Death domains mediate interaction of 
death receptors with death-domain–containing adaptor proteins and then act in the caspase-dependent 
pathway. Death domain containing receptors activate the apoptotic pathway by caspase-8 mediated 
cleavage of the pro-apoptotic Bcl-2 superfamily member BID [74]. This protein interacts with other 
molecules like Bax and Bak, which cause release of mitochondrial cytochrome c and SMAC/DIABLO, 
activating caspase-9 and eventually caspase-3. The other group use TNFR-associated factor to link 
these receptors to serine/threonine protein kinase cascades that regulate gene transcription [75]. 
Because treatment with factors that activate death receptor signaling in cancer cells may be an 
effective anticancer strategy it has been investigated whether PDT can affect this pro-apoptotic pathway. 
The early evidence comes from the study designed by Ahmad et al. [76] where the involvement of 
the cell surface receptor Fas (CD95) pathway in A431 cells in Pc4 mediated PDT was investigated. It 
was observed that a significant time-dependent increase in the protein expression of Fas at 5, 15, 30 
and 60 min post PDT occurred. In an immunoblot, Fas protein was observed as a doublet, which may 
indicate the insoluble and soluble forms of Fas. By using immunoprecipitation it was determined that 
Pc4-PDT resulted in a multimerization of Fas protein leading to its activation. To confirm that PDT 
induced apoptosis is due to Fas activation the involvement of Fas associated death domain level 
(FADD) was examined by using immunoblot analysis. It confirmed a time-dependent increase, for up 
to 1 h post-PDT in Fas protein levels. Pc4-PDT also caused activation of FADD-like interleukin-1 
beta-converting enzyme (FLICE), which was evident from the appearance of cleaved products of pro-
casapase-8. 
To further evaluate the role of Fas in PDT mediated apoptosis, Ali et al. [77] used a model of 
Hypocrellin A (HA) and Hypocrellin B (HB) as photosensitizers in CNE2 and TW0-1 cells. This 
group observed elevated levels both Fas and FasL in both examined cell lines and these higher levels 
coincided with increase in phototoxicity of PDT. The enhanced expression of CD95/CD95L was 
detectable within 2 h after irradiation using HA and HB and was significantly increased at 3 h 
following light exposure. The specific involvement of Fas/FasL system in CNE2 and TW0-1 cell death 
induced by HA and HB was further supported by significant inhibition of apoptosis in the presence of 
either anti-CD95 or anti-CD95L antibodies.  
There is also strong evidence that APO2/TRAIL is involved in PDT mediated apoptosis.  
Schempp et al. [78] used Hypericin mediated PDT in Jurkat cells and by using neutralizing antibodies 
against Fas, FasL, TRAIL and TNFR1 discovered that post PDT apoptosis can be inhibited by 
polyclonal anti-TRAIL antibody. The specificity of the inhibitory activity of this antibody was 
demonstrated by blocking TRAIL mediated killing of Jurkat cells. However, the mechanism of 
Hypericin-PDT mediated apoptosis based on TRAIL/TRAIL-receptors involvement is not clear and it 
may include increased shedding of TRAIL, stabilization of death inducing TRAIL receptors or down 
regulation of decoy receptors. 
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Further support for this hypothesis was provided by Granville et al. [79], who described a two-fold 
increase in the number of cells containing hypo diploid DNA after combined therapy PDT + TRAIL. 
They also described that combined therapy of PDT and Fas-ligand increased the number of apoptotic 
cells seven times. The final conclusion was that Jurkat cells undergoing PDT procedure become more 
sensitive to Fas-ligand and TRAIL induced killing.  
4.1. NF-B Involvement in PDT-Mediated Apoptosis 
Nuclear factor kappa B (NF-B) is a term referring to a group of dimeric transcription factors that 
belong to the Rel family and are regulated via shutting from the cytoplasm to the nucleus in response 
to cell stimulation [80]. The Rel proteins belong to two classes. The first class includes RelA, RelB 
and c-Rel, proteins that are synthesized as mature products and do not require proteolytic processing. 
The second group is encoded by the Nfkb1 and Nfkb2 genes, whose proteins are first synthesized as 
large precursors that require proteolytic processing to produce mature forms. NF-B dimers are held in 
the cytoplasm through specific inhibitors of kappa B, the IBs [81]. IkB members undergo rapid 
ubiquitin-dependent degradation after exposure to a variety of agonists, which activate the IB kinase 
complex (IKK) [82]. This complex induces the phosphorylation-dependent removal of the IB-like  
C-terminal domain of NF-B, which allows dimers to translocate to the nucleus. Once in the nucleus 
the dimers target genes that belong to four broad categories: immunoregulatory and inflammatory 
genes; anti-apoptotic genes; genes that positively regulate cell proliferation; genes that encode negative 
regulators of NF-B. NF-B is also known as an inhibitor of programmed cell death [83]. This factor 
activates transcription of several genes that are known to block the induction of apoptosis by TNF 
superfamily members [84]. The anti-apoptotic factors that are induced by NF-B include cellular 
inhibitors of apoptosis (cIAPs), FLICE and members of Bcl-2 family. NF-B can also attenuate the 
apoptotic response to genotoxic anticancer drugs and radiation therapy [84].  
PDT produces an oxidative stress that can result in activation and translocation of NF-B to the 
nucleus, as originally shown for treatment of L1210 murine leukemia cells with Photofrin and  
light. [85]. The claim that NF-B may be a target for PDT has been convincingly demonstrated by 
Granville et al. [86]. The photodynamic treatment of HL-60 cells with Verteporfin has no detectable 
effect on cellular IB levels by 1 h. Furthermore, lysates prepared up to 3 h post PDT did not contain 
detectable IB degradation products. However, the nuclear lysates revealed low protein levels showing 
reliable assessment of B binding activity. After the PDT procedure, HL-60 cells transfected with a 
Luc reporter gene exhibited increased luciferase activity, confirming that photosensitization leads to 
productive NF-B-mediated gene transcription. The mechanism by which PDT induce NF-B 
translocation to the nucleus is so far unclear, but this study confirmed that NF-B provides an anti-
apoptotic signal for cells exposed to PDT. 
5. Mitogen-Activated Protein Kinases (MAPK) Involvement in PDT-Mediated Apoptosis  
Mitogen-activated protein kinases are proline-directed Ser/Thr protein kinases activated by dual 
phosphorylation on both tyrosine and threonine residues [87]. These enzymes are critical components 
of a complex cellular signaling network that ultimately regulates gene expression in response to variety 
extracellular stimuli. The three well known MAPK families are: the extracellular signal-regulated 
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kinases (ERKs), the c-Jun N-terminal kinases/stress-activated protein kinases (JNKs/SAPKs), and the 
p38 MAPK [88]. Each of these enzymes is a target for phosphorylation cascades in which the 
sequential activation of three kinases constitutes a common signaling pathway. The best characterized 
MAPK pathway is the Ras/Raf/MEK cascade leading to the activation of ERK1/2 in response to 
growth factors [89]. JNK and p38 are key mediators of stress signals and inflammatory response [90].  
A link between SAPK and p38 pathways and apoptosis has been suggested in several studies [91,92]. 
The evidence of the involvement of JNK1 and p38 was provided by Assefa et al. [93]. In hypericin-
mediated PDT of A431, HaCaT, HeLa and L929 cell lines theye observed a rapid and persistent 
activation of JNK1 and severely inhibition of the basal levels of ERK2. It was also demonstrated that 
photo-activated hypericin blocked the EGF-mediated activation of ERK2, and the inhibition of ERK2 
pathway was irreversible. They also observed that JNK1 activation occurred independently from 
caspase activities. Using simultaneous inhibition of both stress kinases they observed significant 
sensitization of cells to PDT-hypericin mediated apoptosis. They concluded that both JNK1 and p38 
MAPK pathways played an important role in cellular resistance to PDT-induced apoptosis with hypericin.  
The involvement of stress kinases in PDT mediated cell death was also investigated by Chan et al. [94]. 
They evaluated the role of JNK1 and involvement of singlet oxygen in triggering the JNK pathway. 
PDT triggered activation of stress kinase pathway in two steps: firstly the formation of singlet oxygen 
induced rapid activation of JNK, which led to activation of the caspase cascade and apoptosis. 
Secondly activated caspase-3 could then act on several apoptotic substrates including PAK2. Cleavage 
of PAK2 released its C-terminal catalytic fragment as a 36 kDa active kinase that can further perform a 
second step in JNK activation. 
Xue et al. [95] investigated the involvement of Etk/Bmx kinase in PDT mediated apoptosis. 
Etk/Bmx is a newly discovered tyrosine kinase, commonly expressed in prostate epithelial and 
carcinoma cells. It might play an important role in the growth, development and anti-apoptotic action 
in epithelial cells. Using an overexpression model in LNcaP cells they found that Etk/Bmx is an 
effector of PI3-kinase and that the PI3-kinase/Etk pathway is involved in the protection of prostate 
carcinoma cells from apoptosis in response to PDT. 
6. Involvement of Other Factors in PDT Mediated Apoptosis  
Ceramide is implicated in the cell-signaling pathway involved in apoptosis as it acts as a second 
messenger to permeabilize the outer mitochondrial membrane and facilitate the release of cytochrome 
c from the mitochondria [96]. Other modes of ceramide-mediated cell death involve the activation of 
stress-activated protein/JUN kinase (SAPK/JNK) [97], dephosphorylation of the retinoblastoma 
protein and upregulation of transcription factors. Evidence of ceramide involvement in PDT-mediated 
apoptosis was provided by Separovic et al. [98]. In phthalocyanine PDT model they demonstrated in 
the U937 cell line elevated levels of ceramide by 45, 37, 67, 118 and 134% at 1, 10, 30, 60 and  
120 min, respectively, after PDT procedure. In CHO cells ceramide generation in response to PDT was 
rapid but did not reach such a high level. Ceramide accumulation was also observed in RIF1 cells. In 
this model ceramide levels were not different from control level for the first 10 min post-PDT but then 
reached a maximum of 118%, maintaining this level up to 2 h. The PDT dose produced a 99% loss of 
clonogenicity, however in RIF1 cell there was no evidence of apoptosis.  
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p21/WAF1 involvement in PDT was investigated by Ahmad et al. [99]. They found that cells 
subjected to PDT resulted in a growth arrest particularly observed in G0-G1 phase. The treatment 
caused an accumulation of 47%, 51% and 69% growth-arrested cells at 3, 6 and 12 h post-PDT, 
respectively. They further assessed the influence of PDT on WAF1/p21 induction and using Western 
blot analysis revealed a significant induction of WAF1/p21 at 3, 6 and 12 h after treatment, when 
compared with basal levels. In addition, PDT resulted in a time-dependent decrease in cyclin D1, cyclin E, 
cdk2 and cdk6. The decrease of cyclin D1 and cdk6 was markedly more pronounced than that of cyclin 
E and cdk2. To confirm this data they investigated the effect of PDT on kinase activities associated 
with cdk. The radioactive kinase activity assay showed that PDT almost universally resulted in a time-
dependent decrease in kinase activities associated with all the cdks and cyclin examined. They also 
examined the effect of PDT on the binding between WAF1/p21-cyklin and WAF1/p21-cdk and also 
cyclin-cdk and found that PDT resulted in increased binding of cyclin D1 and cdk6 toward WAF1/p21, 
whereas the binding of cyclin E and cdk2 did not change. 
7. PDT and Necrosis 
Necrotic cell death has been described as a violent and quick form of degeneration affecting large 
fractions of cell populations, characterized by cytoplasmic swelling, destruction of organelles and 
disruption of the plasma membrane, leading to the release of intracellular contents and consequent 
inflammation [100]. 
Necrosis has been referred to as accidental cell death, caused by physical or chemical damage and 
has generally been considered an unprogrammed process [101]. It is characterized by a pyknotic 
nucleus, cytoplasmic swelling, and progressive disintegration of cytoplasmic membranes, all of which 
lead to cellular fragmentation and release of material into the extracellular compartment. In necrosis, 
decomposition is principally mediated by proteolytic activity, but the precise identities of proteases 
and their substrates are poorly defined [102]. 
Studying the factors and parameters that cause cellular necrosis after PDT is not as easy as studying 
those factors which lead to apoptosis. The crucial factors in determining the type of cell death,  
e.g., apoptosis or necrosis following PDT are: the cell type, the presence of an intact set of apoptosis 
machinery, the subcellular localization of the PS, the light dose applied to activate it locally, and the 
oxygen partial pressure [103]. One factor that can be agreed upon by all commentators is that high 
dose PDT (either a high photosensitizer concentration or a high light fluence or both) tends to cause 
cell death by necrosis, while PDT administered at lower doses tend to predispose cells towards 
apoptotic cell death.  
Nagata and colleagues [104] used the amphiphilic PS ATX-S10 (Na) and human malignant 
melanoma cells and found that light doses that led to less than 70% cytotoxicity induced mainly 
apoptosis; by contrast, most cells appeared necrotic with doses that induced 99% cytotoxicity. A 
common feature of the apoptotic program initiated by PDT is the rapid release of mitochondrial 
cytochrome c into the cytosol followed by activation of the apoptosome and procaspase-3. With PS 
localized in the plasma membrane the photosensitization process can rapidly switch the balance 
towards necrotic cell death likely due to loss of plasma membrane integrity and rapid depletion of 
intracellular ATP [105]. It is also possible that high doses of PDT can photochemically inactivate 
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essential enzymes and other components of the apoptotic cascade such as caspases. For instance, Lavie 
and coworkers [106] used the perylenequinones (hypericin and dimethyl tetrahydroxyhelianthrone) 
and found high dose PDT inhibited apoptosis by interfering with lamin phosphorylation, or by 
photodynamic cross-linking of lamins. 
Xue and Oleinick [107] compared Pc4-mediated PDT of MCF7 cells that lack caspase 3 with the 
same cell line with caspase 3 transfected back in. They found apoptotic indicators only in the caspase 
expressing cells which also showed more loss of viability by an assay involving reduction of a 
tetrazolium dye; however both cell lines showed an equal degree of cytotoxicity by a clonogenic assay.  
Dahle, Steele and Moan reported [108] that the mode of cell death induced by PDT depended on cell 
density. They seeded Madison Darby canine kidney II cells (MDCK II) at two different densities and 
incubated them with meso-tetra(4-sulfonatophenyl)porphine (TPPS4) for 18 h, washed and irradiated 
with blue light. Four hours later the cells were studied by fluorescence microscopy. With <55% total 
cell death the apoptotic fraction was significantly higher for cells in confluent monolayers than for 
cells growing in microcolonies at equitoxic doses. Confluent cells were 2.9 times more sensitive than 
cells in microcolonies partly due to a 1.5 times higher uptake of TPPS4 in monolayer cells. The 
difference in mode of cell death for the different cell densities was not related to any observable 
difference in subcellular localization pattern of TPPS4 at equitoxic doses of PDT. 
8. PDT and Autophagy 
Autophagy is a catabolic cellular mechanism that allows the cell to maintain a balance between the 
synthesis, degradation, and recycling of cellular products [109]. A variety of autophagic processes 
exist, all of which involve the lysosomal degradation of the cellular organelles and proteins. The most 
well-known mechanism proceeds in the following manner: A double membrane structure called 
autophagosome surrounds the target region, creating a vesicle that separates its contents from the rest 
of the cytoplasm. This vesicle is then transported and fused to the lysosome, forming a structure called 
the autophagolysosome, the contents of which are subsequently degraded by lysosomal hydrolases [110]. 
Besides facilitating the disposal of unwanted proteins, organelles, and invading microorganisms, 
autophagy also allows a cell to reallocate its nutrients from unnecessary processes to life-essential ones 
in times of starvation or stress. 
The term ―autophagy‖ originated in 1963 at the Ciba Foundation Symposium on Lysosomes, where 
it was used to describe the presence of membrane vesicles that contain disintegrating organelles and 
cytoplasm components. Evidence soon confirmed that autophagy is an adaptive, energy-generating 
process. Molecular control of autophagy came into focus in the late 1990s. Signaling pathways 
governing this process became better understood after the identification of the target of rapamycin 
kinase (TOR), which controls cell growth and protein synthesis [111]. In 1997, Ohsumi‘s group 
showed that yeast autophagy is similar to that of mammals, which allowed them to analyze the process 
in the genetically tractable yeast system. This study led to the discovery of the first autophagy-related 
gene, ATG1. Shortly thereafter, the first mammalian autophagy genes were identified [112].  
One of the first diseases associated with autophagy was cancer [113]. It was discovered that 
Beclin1, an essential protein for autophagy, is also a tumor suppressor [114]. Further studies on the 
role of autophagy in cancer revealed some interesting properties of the disease. Initially, autophagy 
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suppresses tumor growth through its production of Beclin1. This changes as the tumor becomes more 
advanced; autophagy begins to promote tumor progression by providing the mechanism for cells in the 
central, low nutrient, part of the tumor to obtain the energy that they need to stay alive. It was also 
found that autophagy blocks apoptotic pathways, thereby protecting cancer cells from treatment [114]. 
On the other hand, some cancer therapies induce autophagic cell death of tumor cells. This two-sided 
effect of autophagy on tumors can be exploited by anticancer therapy to provide better treatment for 
cancer patients.  
It is still unclear exactly how autophagy affects the outcome of PDT [66,115,116]. In general, 
mammalian cells use autophagy as a defense against ROS mediated damage by clearing the cell of 
damaged organelles [117]. Depending on the type of ROS and degree of oxidative injury, PDT may 
stimulate autophagy [118] that either acts in a cytoprotective manner or induces autophagic cell  
death [119]. Autophagy may play a role in PDT induced apoptosis, but the two processes can also 
occur independently of one another [120]. A study done on murine leukemia L1210 cells found that a 
wave of autophagy occurs right before apoptosis [121]. It was also found that prevention of autophagy 
by silencing the Agt7 gene allowed photo-killing to occur at lower light doses. This observation is 
consistent with the theory that autophagy is a defense mechanism against PDT induced ROS [122]. 
The situation is different for tumor cells that do not have the ability to undergo apoptosis through a 
deficiency in Bax and Bac, which regulate the apoptotic pathway. In these cells, PDT induced 
autophagy stimulates a necrotic, caspase independent cell death [64]. Suppression of autophagy in 
apoptosis-deficient cells resulted in the inhibition of cell death during PDT. In general, the induction of 
autophagy in PDT treated cells occurs independently of an apoptotic outcome. While autophagy seems 
to play a pro-survival role in tumor cells that are capable of apoptosis, it has been shown to promote 
death in cells that are apoptosis-deficient.  
In order to understand how PDT affects autophagy it is important to take note of the PDT affected 
proteins that are involved in this mechanism. Many proteins, some directly involved in the autophagic 
process, are damaged by PDT induced ROS. Some ER and mitochondrial photosensitizers cause 
damage to Bcl-2, to which Beclin1 (a pro-autophagic protein) binds. The IP3 protein, a regulator of the 
autophagic process associated with the ER [123,124] is affected by phthalocyanine photosensitizer  
Pc 4 [125]. The photosensitizer AlPcS causes damage to the mammalian target of rapamycin, mTOR, a 
cell growth regulator that takes part in the autophagic signaling pathway [126]. Other proteins, like 
Beclin1, Atg5, and Atg7, appear to be unaffected by PDT. Although many proteins involved in the 
autophagic process are photodamaged by PDT, it appears that those involved in the formation of 
autophagosomes remain active [120].  
PDT can also affect autophagy by damaging organelles that are directly involved in the process. 
Several photosensitizers target autophagy-related organelles such as lysosomes and endosomes. When 
tetra(4-sulphonatophenyl)-porphine (TPPS4) photosensitizer is used photo-oxidation of the organelle 
matrix occurs [127]. In this type of PDT, lysosomal enzymes are inactivated before the membrane 
ruptures, which allows for specific targeting of this organelle without causing damage to the rest of the 
cell. This treatment can be used to selectively enrich autophagosomes [128]. On the other hand, NPe6 
and TPPS2 photosensitizers bind to the lysosomal membrane, causing it to rupture upon irradiation. 
The released, but not neutralized proteases can cause induction of apoptosis by cathepsin-mediated 
cleavage of Bid [129]. The lysosomes, autophagosomes, endosomes, and autolysosomes of the cells 
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treated with this amphiphilic photosensitizer will have it in their membranes. Upon irradiation, the 
membranes will break and release their contents into the cytoplasm. Based on these results, it can be 
concluded that the effect of PDT on the autophagy of a tumor cell depends on the type of 
photosensitizer used. 
The effects of a damaged lysosome on the autophagic process were explored in an autophagic flux 
study of murine hepatoma 1c1c7 cultures. These cultures were sensitized with NPe6 and irradiated 
with LD90 light dose. Acridine orange (AO) staining of acidic organelles was done in order to observe 
the effect of PDT on the lysosome. No lysosomal damage was observed when cells were exposed to 
either light or photosensitizer alone. In those cells that received PDT, AO staining was completely lost 
within an hour, and within two hours autophagosome accumulation was observed [130]. This indicates 
that autophagosomes can be formed in the absence of lysosomes, but autophagy cannot be completed 
due to the lack of these organelles. 
Based on studies with various cancer lines and photosensitizers it can be concluded that PDT 
directly induces autophagy. This is independent of photosensitizer target, as autophagy was observed 
with photosensitizers that localize in the ER, mitochondria, lysosomes, and endosomes. A second 
conclusion that can be drawn is that apoptosis often occurs in cells that are already undergoing 
autophagy and is also a result of PDT. The rates of autophagy and apoptosis depend on the cancer cell 
type, photosensitizer, and light dosage. Depending on cell type, autophagy will either promote or 
prevent cell death from PDT. In cells that are able to undergo apoptosis autophagy alleviates the 
destructive effects of PDT by recycling damaged organelles [131]. This opens up a possibility that 
PDT of these cancer cells can be enhanced by suppressing pro-autophagic proteins. Autophagy has the 
opposite effect on cells that are apoptosis-deficient, promoting cell death through necrosis. The last 
conclusion that can be made is that autophagic processes are compromised, but not prevented, in PDT 
protocols that employ lysosome targeting photosensitizers. In these procedures, autophagy is initiated 
by formation of autophagosomes but cannot be completed by fusing with the lysosome. This is because 
the proteins involved in autophagosome formation (Beclin1, Atg5) are not photodamaged by PDT.  
9. Conclusions  
PDT can lead to all three forms of cell death, namely apoptosis, necrosis and autophagy (Figure 4). 
The response to PDT may vary not only with the cell type or its genetic or metabolic potential but also 
with the experimental model, total fluence delivered, different types of photosensitizers and their 
intracellular localization. The initial site of PDT-related damage may determine which cell death 
pathway is initially activated. The extent of PDT related damage may also regulate how the PDT 
treated cells respond. It is possible that the autophagy process is activated as an initial rescue 
mechanism, when the PDT damaged cells try to contain and removed damaged proteins. Only when 
the PDT damage is sufficiently robust and the cells are damaged beyond repair does apoptosis occur. 
PDT, at its highest dose may also lead to necrosis, as the proteins that participate in both autophagy 
and apoptosis may be immediately destroyed and the cellular integrity may be broken.  
It is also important to bear in mind that most of the reported in vitro data are also difficult to 
translate into the in vivo situation where unequal light distribution or inhomogeneous photosensitizer 
accumulation may lead to a variable cellular response within PDT treated tumors. Additionally, the 
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shutdown of tumor vessels may lead to local depletion of nutrients and oxygen and therefore trigger 
secondary PDT related necrosis. Lastly, as PDT leads to activation of tumor directed immune 
response, some cancer cells are killed via apoptosis by cytotoxic T cells.  
The understanding of the cascade of events playing a role in PDT-mediated apoptosis is far from 
complete. Defining these events will hopefully result in designing better PDT protocols, which could 
have wider applications as a cancer therapeutic modality.  
Figure 4. Cell death pathways in PDT. The mode of cell death observed after PDT to some 
extent depends on the intracellular localization of the PS and PDT related damage to that 
organelle. PDT with PS localizing in mitochondria will lead to loss of membrane 
permeability and release of pro-apoptotic mediators while ER damage will release cellular 
deposits of calcium. PS that accumulates in lysosomes will release proteolytic enzymes 
upon illumination. Lysosomes may also fuse with autophagosomes to hydrolyse damaged 
organelles and recycle them during autophagy. In the excess of damage the cell will not 
survive despite initiation of autophagy. Necrosis as well as autophagy may be a dominant 
cell death mode after PDT when apoptosis is dysfunctional. It should be remembered that 
several PS may localize in more than one organelle and the activation of cell death 
pathways may occur concurrently (adapted from Oleinick et al. [132]).  
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